Press releases
These press releases are intended for journalists and analysts/investors.
-
Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer
GlaxoSmithKline plc (LSE:GSK) today announced its decision to stop the MAGRITi trial
Read more -
ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool
ViiV Healthcare today announced new collaborations with the goal of increasing access to its HIV medicine
Read more -
GSK brings New Zealand to the forefront in new Panadol® brand campaign
A Kiwi father and son will star in a brand new Panadol campaign to be aired on television screens globally
Read more -
GSK Recalls Nicotine Lozenges from Warehouses and Distributors
GSK is in the process of voluntarily recalling from warehouses and distributors a number of batches of nicotine lozenges sold globally
Read more -
New PBS listing for patients with advanced soft tissue sarcoma
Treatment options for advanced Soft Tissue Sarcoma (STS) have been broadened with a new Pharmaceutical Benefits Scheme (PBS)
Read more -
TGA approves GSK’s combination of TAFINLAR®(dabrafenib) and MEKINIST® (trametinib)
GSK Australia announced today that the Therapeutics Goods Administration (TGA) has approved the combination of two oral targeted therapies
Read more -
Supply of Varilrix® and Priorix-Tetra® resumes
GSK recently identified a global manufacturing issue impacting some of our varicella- containing vaccines during routine quality testing
Read more -
Poppy Crop Security Update
GlaxoSmithKline (GSK) is aware that there may be an increased concern in poppy crop security following recent media reports
Read more -
GSK announces start of Phase lll study for mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis
GlaxoSmithKline (GSK) today announced the start of a Phase III study to evaluate the efficacy and safety of mepolizumab
Read more -
Supply of Varilrix® and Priorix-Tetra®
GSK recently identified a global manufacturing issue relating to some of our varicella-containing vaccines
Read more -
GSK and MMV announce FDA Breakthrough Therapy designation for tafenoquine for Plasmodium vivax malaria
GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) announced today that the U.S. Food and Drug Administration (FDA)
Read more -
GSK announces changes to its global sales and marketing practices
GSK announced today changes to the way products are marketed and sold to healthcare professionals to further align the company’s activities
Read more -
Poppy Trials Making Positive Progress
Victoria is one step closer to commercial poppy growing, with scientific trials undertaken by GlaxoSmithKline (GSK) Australia
Read more -
GSK recalls from trade two batches of Children’s Panadol® 1-5 years Suspension
GSK is working with the Therapeutic Goods Administration (TGA) to recall two batches of Children’s Panadol® 1-5 years Suspension
Read more -
New medicine listed on the PBS for the treatment of metastatic melanoma in Australia
The listing of Tafinlar® (dabrafenib mesilate) on the Pharmaceutical Benefits Scheme (PBS) will lead to improved access to the medicine
Read more -
URGENT SAFETY ALERT - Syringe Dosing Device for Children’s Panadol
GlaxoSmithKline (GSK) is initiating a recall of Children’s Panadol Baby Drops Syringe dosing device due to possible inaccurate placement
Read more -
GSK award shines light on seismic change to epilepsy diagnosis
GSK has awarded Professor Ingrid Scheffer the 2013 GlaxoSmithKline Award for Research Excellence (ARE) for helping to transform
Read more -
GSK Adult Immunisation Grants 2013
Four projects set to increase adult immunisation rates across Australia have received funding through the GSK 2013 Adult Immunisation Grants
Read more -
Monash-GSK pharmaceutical partnership wins two prestigious National B-HERT Collaboration Awards
GSK Australia’s manufacturing R & D team and the Monash Institute of Pharmaceutical Sciences (MIPS) received two industry awards
Read more -
New partnership between GSK and the Bill & Melinda Gates Foundation to accelerate research into vaccines for global health needs
GSK and the Bill & Melinda Gates Foundation (BMGF) today announced the launch of a new joint initiative that will endeavour to make vaccines
Read more
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Careers
GSK is a place where talented people do amazing things. Where you are encouraged to be you and create a meaningful impact.
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products.
